ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7

Meng, Yiling; Bian, Lei; Zhang, Meichao; Zhou, Pingting; Zhang, Suning; Ying, Yingxia; Yang, Sunhu; Liu, Yuanhua; Yao, Yuan; Li, Dong

doi:10.7150/ijbs.85424



Theranostics

International Journal of Medical Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Biol Sci 2024; 20(4):1180-1193. doi:10.7150/ijbs.85424 This issue Cite

Research Paper

ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7

Yiling Meng^1,#, Lei Bian^1,2,#, Meichao Zhang^1,#, Pingting Zhou¹, Suning Zhang³, Yingxia Ying¹, Sunhu Yang⁴, Yuanhua Liu^5,✉, Yuan Yao^1,✉, Dong Li^1,✉

1. Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
2. State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
3. Department of Emergency, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
4. Department of General Surgery, Shanghai university of TCM Shanghai TCM-integrated hospital, Shanghai, China.
5. Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China.
# These authors have contributed equally to this work.

✉ Corresponding authors: Dong Li, Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; E-mail: lidongedu.cn. Yuan Yao, Department of Radiation Oncology, Shanghai N More

Citation:

Meng Y, Bian L, Zhang M, Zhou P, Zhang S, Ying Y, Yang S, Liu Y, Yao Y, Li D. ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7. Int J Biol Sci 2024; 20(4):1180-1193. doi:10.7150/ijbs.85424. https://www.ijbs.com/v20p1180.htm

Other styles

Abstract

Chemoresistance is an obstacle of improving pancreatic cancer (PC) prognosis. However, the biological function of ISG15 in PC and whether it correlates with the resistance to chemotherapy are still unknown. Here, we aimed to reveal the clinical significance of ISG15 in PC and its regulatory mechanism in cancer progression and resistance to therapy. The level of ISG15, a protein involved in post-translational modifications, is elevated in PC tissues. Clinically, higher ISG15 expression correlates with higher PC grades, stronger resistance to treatment and poorer prognosis. Moreover, ISG15 promotes the proliferation, migration, invasion, colony formation of PC cells and resistance to Gemcitabine, a classic chemotherapeutics for PC, both in vitro and in vivo. ISG15 promotes progression and resistance to therapy in PC cells by binding to ATG7, reducing its degradation, and thereby leading to enhanced autophagy in PC cells. ISG15 may be used as both a potential diagnosis marker and sensitizer for chemotherapeutics such as Gemcitabine during PC intervention.

Keywords: pancreatic cancer, ISG15, autophagy, ATG7, Gemcitabine

Citation styles

APA

Meng, Y., Bian, L., Zhang, M., Zhou, P., Zhang, S., Ying, Y., Yang, S., Liu, Y., Yao, Y., Li, D. (2024). ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7. International Journal of Biological Sciences, 20(4), 1180-1193. https://doi.org/10.7150/ijbs.85424.

ACS

Meng, Y.; Bian, L.; Zhang, M.; Zhou, P.; Zhang, S.; Ying, Y.; Yang, S.; Liu, Y.; Yao, Y.; Li, D. ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7. Int. J. Biol. Sci. 2024, 20 (4), 1180-1193. DOI: 10.7150/ijbs.85424.

NLM

CSE

Meng Y, Bian L, Zhang M, Zhou P, Zhang S, Ying Y, Yang S, Liu Y, Yao Y, Li D. 2024. ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7. Int J Biol Sci. 20(4):1180-1193.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.